Regeneron Pharmaceuticals (REGN) Short-term Investments (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Short-term Investments of $5.5 billion for Q2 2026, up 1.19% year-over-year from $5.5 billion in Q2 2025, and down 4.36% quarter-over-quarter from $5.8 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Short-term Investments (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $5.5 billion for Q2 2026.
- In Q2 2026, Short-term Investments rose 1.19% year-over-year to $5.5 billion; the TTM figure through Jun 2026 stood at $5.5 billion (up 1.19% YoY), while the FY2025 annual figure was $5.5 billion, down 15.9% from the prior year.
- Short-term Investments for Q2 2026 stood at $5.5 billion, down from $5.8 billion in the prior quarter.
- The five-year high for Short-term Investments was $8.1 billion in Q4 2023, with the low at $3.5 billion in Q3 2022.
- The 5-year median for Short-term Investments is $5.7 billion (2026), against an average of $6.0 billion.
- The sharpest annual moves came in 2022 and 2025: Short-term Investments jumped 126.87% in 2022, then plunged 33.57% in 2025.
- Regeneron Pharmaceuticals' Short-term Investments stood at $4.6 billion in 2022, then soared by 75.02% to $8.1 billion in 2023, then dropped by 19.6% to $6.5 billion in 2024, then decreased by 15.9% to $5.5 billion in 2025, then climbed by 0.94% to $5.5 billion in 2026.
- Business Quant data shows REGN's Short-term Investments at $5.5 billion in Q2 2026, $5.8 billion in Q1 2026, and $5.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.54 Bn |
| Mar 31, 2026 | 5.79 Bn |
| Dec 31, 2025 | 5.49 Bn |
| Sep 30, 2025 | 5.94 Bn |
| Jun 30, 2025 | 5.47 Bn |
| Mar 31, 2025 | 5.26 Bn |
| Dec 31, 2024 | 6.52 Bn |
| Sep 30, 2024 | 7.78 Bn |
| Jun 30, 2024 | 7.89 Bn |
| Mar 31, 2024 | 7.92 Bn |
| Dec 31, 2023 | 8.11 Bn |
| Sep 30, 2023 | 7.76 Bn |
| Jun 30, 2023 | 6.99 Bn |
| Mar 31, 2023 | 5.04 Bn |
| Dec 31, 2022 | 4.64 Bn |
| Sep 30, 2022 | 3.53 Bn |
| Jun 30, 2022 | 4.17 Bn |
| Mar 31, 2022 | 3.70 Bn |
| Dec 31, 2021 | 2.81 Bn |
| Sep 30, 2021 | 2.36 Bn |